SCHEMBL2496709

SCHEMBL2496709

CC(C)(C)OC(=O)Nc1ccccc1NC(=O)c1ccc(CN(CCCN2CCOCC2)C(=O)NCCc2ccccc2F)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.46
MAPT P10636 1/20 0.46
KDM1A O60341 1/20 0.45
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 2/20 0.45
LMNA P02545 2/20 0.45
CD274 Q9NZQ7 1/20 0.45
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
BCL3 P20749 2/20 0.42
PKM P14618 2/20 0.42
GAA P10253 1/20 0.42
NAMPT P43490 1/20 0.42
POLB P06746 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2474704 0.93 HSD17B10 (0.47) HSD17B10MAPTKDM1AALDH1A1KDM4E
SCHEMBL2499714 0.92 KDM1A (0.52) HSD17B10KDM1AALDH1A1KDM4ELMNA
SCHEMBL3835937 0.91 NAMPT (0.48) KDM1AALDH1A1CD274TSHRBCL3
SCHEMBL3230832 0.91 HSD17B10 (0.46) HSD17B10MAPTKDM1AALDH1A1KDM4E
SCHEMBL3836221 0.89 POLB (0.48) KDM1AALDH1A1KDM4ECD274BCL3
SCHEMBL2473184 0.88 HSD17B10 (0.50) HSD17B10MAPTKDM1AALDH1A1KDM4E
SCHEMBL2477116 0.87 KDM1A (0.50) HSD17B10MAPTKDM1AALDH1A1KDM4E
SCHEMBL2476081 0.87 KDM4E (0.46) HSD17B10MAPTKDM1AALDH1A1KDM4E
SCHEMBL2477790 0.86 HSD17B10 (0.49) HSD17B10KDM1AALDH1A1KDM4ECD274
SCHEMBL7998610 0.85 NAMPT (0.45) KDM1ACD274TSHRNAMPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 HSD17B10 2033/4885MAPT 1576/4885KDM1A 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.